Founded in 1981 by two pioneering scientists, Repligen is a leader today in bioprocessing filtration technologies, pre-packed chromatography columns and Protein A ligand manufacturing.
Since it’s founding in 1981, Repligen has been a leading expert in Protein A. Repligen scientists first cloned the gene for Protein A in 1982, and the company introduced the world’s first recombinant form of the ligand in 1985. To this date, most of the world's monoclonal antibodies are purified on Repligen's Protein A.
Beginning in 2010, Repligen entered a period of rapid growth propelled by a combination of R&D innovation and strategic acquisitions. This growth accelerated in 2012 when Repligen made the strategic decision to focus on bioprocessing products and systems.
- Innovative products focused on improving process efficiency and process economics were developed and launched.
- Transformative and strategic acquisitions increased the depth and breadth of product offerings.
In 2016, Repligen was named one of the Top 500 fastest growing companies in North America. This growth continues today, driven by the technology leadership of Repligen products, and the company's commitment to always put the customer first.
Repligen was founded in 1981 by two distinguished scientists who pioneered breakthrough advances in science and technology.
Alexander Rich was co-Chair of the Repligen Board of Directors until 2014. He was a Professor at the Massachusetts Institute of Technology since 1958. Considered a founding father of the field of molecular biology, he received the National Medal of Science in 1995. He passed away on April 27, 2015 at 90 years old.
Paul Schimmel is the Ernest and Jean Hahn Professor at The Skaggs Institute for Chemical Biology at The Scripps Research Institute. He formerly was the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics in the Department of Biology at the Massachusetts Institute of Technology. His principal scientific contributions include the discovery of “The Second Genetic Code" and expansion of the functional genome.